Other - , ,
We are a young biotech startup and our aim is to develop the next generation of influenza diagnostic tests in order to prevent the spread of the virus. Influenza virus is a big problem. It affects over 10% of the world's population every year with 650.000 deaths annually. The economical impact is massive: 87 billions US dollars per year and these numbers continue to grow. The market is dominated by rapid tests with an average sensitivity of only 50%, not enough to be deployed efficiently. Our test is different: it shows a higher probability of detection and an increase in diagnostic performance.
Varnish
Wix
Google Cloud Hosting
Mobile Friendly